Provided by Tiger Trade Technology Pte. Ltd.

COYA THERAPEUTICS INC

4.43
-0.0900-1.99%
Volume:66.00K
Turnover:297.40K
Market Cap:103.87M
PE:-4.07
High:4.66
Open:4.59
Low:4.41
Close:4.52
52wk High:7.75
52wk Low:3.71
Shares:23.45M
Float Shares:17.54M
Volume Ratio:1.33
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0897
EPS(LYR):-1.2700
ROE:-60.54%
ROA:-32.27%
PB:2.40
PE(LYR):-3.49

Loading ...

Coya Therapeutics to host webinar on repetitive head trauma, brain inflammation and neurodegenerative disease

Reuters
·
Jun 15

Coya Therapeutics Says Phase 2 ALS Study Enters Blinded Extension Phase

MT Newswires Live
·
Jun 08

Coya Therapeutics Announces the First Cohort of Patients in the Alstars Trial Have Begun the Blinded Active-Treatment Extension Phase

THOMSON REUTERS
·
Jun 08

Coya Therapeutics Initiated at Buy by Roth Capital

Dow Jones
·
Jun 05

Coya Therapeutics initiated with a Buy at Roth Capital

TIPRANKS
·
Jun 05

Coya Therapeutics releases investor presentation on Treg-directed combination therapies for neurodegenerative diseases

Reuters
·
Jun 01

Coya Therapeutics presents ALSTARS Phase 2 trial design at ALS Drug Development Summit

Reuters
·
May 27

Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Beta Bionics, Inc. (BBNX) and Arvinas Holding Company (ARVN)

TIPRANKS
·
May 22

Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street

TIPRANKS
·
May 13

Coya Therapeutics announces annual shareholder meeting

Reuters
·
May 13

Coya Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Coya Therapeutics: Entered Into Sales Agreement, May Offer and Sell From Time to Time Shares of Co's Common Stock for up to $30 Mln

THOMSON REUTERS
·
May 12

Coya Therapeutics enters at-the-market equity sales agreement for up to $30 million stock offering

Reuters
·
May 12

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

TIPRANKS
·
May 12

Coya Therapeutics Q1 FY26 net loss narrows to $7.2 million

Reuters
·
May 12

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 12

Coya Therapeutics Q1 Net Income USD -7.2 Million

THOMSON REUTERS
·
May 12

Coya Therapeutics wins FDA fast track status for ALS drug COYA 302

Reuters
·
May 12

Coya Therapeutics Inc - Conducting Phase 2 Alstars Trial of Coya 302 for ALS

THOMSON REUTERS
·
May 12

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for Coya 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

THOMSON REUTERS
·
May 12